3月4日，据CDE官网消息，阿斯利康全球研发（中国）有限公司、阿斯利康制药有限公司、上海合全医药有限公司联合申请药品“Ceralasertib薄膜包衣片”，获得临床试验默示许可，受理号CXHB2400299。
公示信息显示，药品“Ceralasertib薄膜包衣片”适应症：与度伐利尤单抗联合治疗晚期实体瘤患者。
阿斯利康全球研发（中国）有限公司，成立于2021年，位于上海市，是一家以从事研究和试验发展为主的企业。企业注册资本5000万人民币，实缴资本5000万人民币。
通过天眼查大数据分析，阿斯利康全球研发（中国）有限公司参与招投标项目1次，专利信息2条，此外企业还拥有行政许可1个。
主要股东信息显示，阿斯利康全球研发（中国）有限公司由阿斯利康大陆有限公司 ASTRAZENECA CONTINENT B.V.持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.